Lupin is currently trading at Rs. 732.90, up by 10.55 points or 1.46% from its previous closing of Rs. 722.35 on the BSE.
The scrip opened at Rs. 730.00 and has touched a high and low of Rs. 733.00 and Rs. 723.50 respectively. So far 1178 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 882.15 on 02-May-2019 and a 52 week low of Rs. 646.20 on 07-Oct-2019.
Last one week high and low of the scrip stood at Rs. 739.00 and Rs. 699.00 respectively. The current market cap of the company is Rs. 32719.89 crore.
The promoters holding in the company stood at 46.93%, while Institutions and Non-Institutions held 38.99% and 13.80% respectively.
Lupin has received approval for its Leflunomide Tablets USP, 10 mg and 20 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Arava Tablets, 10 mg and 20 mg, of Sanofi-Aventis. The product would be manufactured at Lupin's Pithampur (Unit 1) facility, India.
Leflunomide Tablets USP, 10 mg and 20 mg, are indicated for the treatment of adults with active rheumatoid arthritis (RA). Leflunomide Tablets USP (RLD: Arava Tablets) had an annual sales of approximately $44 million in the U.S. (IQVIA MAT December 2019).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
